Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-07T08:41:42.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision tag was updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T17:45:10.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.4.1 replaces the previous v3.4.0 on the page.
    Difference
    0.1%
    Check dated 2026-02-06T11:16:28.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    New UI options Show glossary and Hide glossary were added, and a revision note at the bottom now shows Revision: v3.4.0. The terms 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were adjusted in wording/capitalization.
    Difference
    0.4%
    Check dated 2026-01-23T04:48:46.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; this appears to be a maintenance/version update rather than changes to page content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-16T01:51:16.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Location details are reorganized: a new Locations section lists Beijing Municipality, Guangdong, Jilin, Shandong, and Sichuan as study sites; the prior separate location blocks are removed. The HHS Vulnerability Disclosure link is removed and the page revision is updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-18T20:40:59.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.